Abstract 376P
Background
This study aimed to explore the beneficial of intensive nutrition intervention with intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy in the treatment of patients with locally advanced nasopharyngeal carcinoma.
Methods
174 locally advanced nasopharyngeal carcinoma patients (LANPC) receiving radical radiotherapy and concurrent cisplatin-based chemotherapy were enrolled from December, 2000 to December, 2016. Patients were divided into two groups as NI group(which received intensive, individualized nutrition education counseling and oral supplements if required), and UC group (general advice and nutrition booklet, without nutrition education). Propensity score matching was performed to balance the baseline differences between the two groups.
Results
Following one-to-one propensity score matching, survival outcomes for the matched data set indicated that the NI group achieved higher overall survival and failure-free survival (P<0.05) compared with UC. Subgroup analysis revealed that NI was associated with significantly improved OS (Hazard ratio [HR] =1.577, 95% Confidence interval [CI] = 1.055–2.357, P < 0.05) and FFS (HR = 1.53, 95% CI = 1.022–2.29, P<0.05). Additionally, the differences of the main adverse reactions after treatment between the two group were not statistically significant (P>0.05).
Conclusions
Early and intensive NI promoted beneficial outcomes in ameliorating the prognosis in loco-regionally advanced NPC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract